

RESEARCH ARTICLES

CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma

M. Romero-Cristóbal, A. Clemente-Sánchez, E. Ramón, L. Téllez, E. Canales, O. Ortega-Lobete, E. Velilla-Aparicio, M.-V. Catalina, L. Ibáñez-Samaniego, S. Alonso, A. Colón, A.-M. Matilla, M. Salcedo, A. Albillos, R. Bañares and D. Rincón 100645

Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status

M.-H. Lee, P.-F. Wu, T.-I. Chen, C. Chan, H.-H. Lin, Y.-H. Huang, H.-Y. Chen, Y.-T. Lin and C.-J. Chen 100634

Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial)

F. Marcellin, A. Mourad, M. Lemoine, C. Kouanfack, M. Seydi, P. Carrieri, A. Attia, C. Protopopescu, K. Lacombe and S. Boyer 100665

Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer

T.D. Christensen, E. Maag, O. Larsen, C.L. Feltoft, K.R. Nielsen, L.H. Jensen, B. Leerhøy, C.P. Hansen, I.M. Chen, D.L. Nielsen and J.S. Johansen 100648

Identification of selective hepatitis delta virus ribozyme inhibitors by high-throughput screening of small molecule libraries

E.D. Tseligka, S. Conzelmann, Y. Cambet, T. Schaer, F. Negro and S. Clément 100652

Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes

S. Duponchel, L. Monnier, J. Molle, N. Bendridi, M.R. Alam, A. Gaballah, B. Grigorov, A. Ivanov, M. Schmiel, M. Odenthal, M. Ovize, J. Rieusset, F. Zoulim and B. Bartosch 100647

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

R. Burm, F. Van Houtte, L. Verhoye, A.A. Mesalam, S. Ciesek, P. Roingear, H. Wedemeyer, G. Leroux-Roels and P. Meuleman 100646

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

B. Maasoumy, P. Ingiliz, C.D. Spinner, C. Cordes, H.-J. Stellbrink, J. Schulze zur Wiesch, S.M. Schneeweiß, K. Deterding, T. Müller, J. Kahlhöfer, P. Dörge, M. von Karpowitz, M.P. Manns, H. Wedemeyer, M. Cornberg and for the HepNet Acute HCV-V Study Group 100650

Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD

J. Linge, P. Nasr, A.J. Sanyal, O. Dahlqvist Leinhard and M. Ekstedt 100663

Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis

F. Villeret, S. Dharancy, D. Erard, A. Abergel, L. Barbier, C. Besch, O. Boillot, K. Boudjema, A. Coilly, F. Conti, C. Corpechot, C. Duvoux, F. Faitot, S. Faure, C. Francoz, E. Giostra, J. Gugenheim, J. Hardwigsen, M.-N. Hilleret, J.-B. Hiriart, P. Housset-Debry, N. Kamar, G. Lassailly, M. Latournerie, G.-P. Pageaux, D. Samuel, C. Vanlemmens, F. Saliba and J. Dumortier 100668

Registration of Clinical Trials

JHEP Reports endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.